RecruitingPhase 3NCT05372718

Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT Trial

Multicenter, Open-label, Randomized Clinical Trial of Efficacy and Safety of the Thrombolysis With Recombinant Non-immunogenic Staphylokinase (Fortelyzin®) in Patients With ALI vs Surgery


Sponsor

Supergene, LLC

Enrollment

170 participants

Start Date

Dec 26, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Objective: to evaluate the efficacy and safety of intra-arterial intrathrombus administration of the recombinant non-immunogenic staphylokinase (Fortelyzin®) in patients with acute limb ischemia (ALI) vs surgery.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Men and women aged 18 and older;
  • Diagnosis of I-II b degree of ALI;
  • Patient consent to use reliable contraceptive methods throughout the study and for 3 weeks after:
  • women who have a negative pregnancy test and use the following contraceptives: intrauterine devices, oral contraceptives, contraceptive patch, prolonged injectable contraceptives, double barrier method of contraception. Women who are not fertile can also take part in the study (documented conditions: hysterectomy, tubal ligation, infertility, menopause for more than 1 year);
  • men using barrier contraception. The study may also involve men who are not fertile (documented conditions: vasectomy, infertility);
  • Availability of signed and dated informed consent of the patient to participate in the study.

Exclusion Criteria8

  • Extensive bleeding at present;
  • Intracranial (including subarachnoid) hemorrhage at present;
  • Recent gastrointestinal bleeding (within 10 days);
  • Major surgery or major trauma within the previous 3 months, recent traumatic brain injury;
  • Systolic blood pressure above 180 mm Hg or diastolic blood pressure above 110 mm Hg or the need for intravenous drugs to lower blood pressure to these limits;
  • Pregnancy, lactation;
  • Known hypersensitivity to Fortelyzin®;
  • Platelet count less than 100,000/µL

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRecombinant non-immunogenic staphylokinase (Fortelyzin®)

lyophilisate for preparation a solution

PROCEDUREsurgical methods of treatment

Endovascular intervention, open surgery and/or bypass surgery in accordance with the current National Guidelines


Locations(8)

Kursk city emergency hospital

Kursk, Kursl Region, Russia

Sergiyev Posad Regional Clinical Hospital

Sergiyev Posad, Moscow Oblast, Russia

Kaliningrad Regional Clinical Hospital

Kaliningrad, Russia

Kazan City Hospital No. 7

Kazan', Russia

S.S. Yudin City clinical hospital

Moscow, Russia

S.P. Botkin Moscow Multidisciplinary Scientific and Clinical Center

Moscow, Russia

Ufa Emergency City Hospital

Ufa, Russia

Volgograd City Clinical Hospital of Emergency #25

Volgograd, Russia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05372718


Related Trials